DecisionPoint Systems, Inc.

2024 Q2 Form 10-Q Financial Statement

#000121390024043159 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.834M
YoY Change -67.54%
Cash & Equivalents $5.834M
Short-Term Investments
Other Short-Term Assets $4.756M
YoY Change 49.14%
Inventory $1.193M
Prepaid Expenses
Receivables $19.29M
Other Receivables $0.00
Total Short-Term Assets $31.08M
YoY Change -41.93%
LONG-TERM ASSETS
Property, Plant & Equipment $2.889M
YoY Change 57.18%
Goodwill $22.20M
YoY Change 111.49%
Intangibles $7.317M
YoY Change 77.51%
Long-Term Investments
YoY Change
Other Assets $172.0K
YoY Change 282.22%
Total Long-Term Assets $41.01M
YoY Change 78.22%
TOTAL ASSETS
Total Short-Term Assets $31.08M
Total Long-Term Assets $41.01M
Total Assets $72.08M
YoY Change -5.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.58M
YoY Change -37.34%
Accrued Expenses $6.495M
YoY Change 4173.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $1.003M
YoY Change 0.0%
Total Short-Term Liabilities $36.85M
YoY Change -9.16%
LONG-TERM LIABILITIES
Long-Term Debt $3.388M
YoY Change -69.59%
Other Long-Term Liabilities $6.000K
YoY Change 0.0%
Total Long-Term Liabilities $3.394M
YoY Change -69.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.85M
Total Long-Term Liabilities $3.394M
Total Liabilities $53.09M
YoY Change -9.83%
SHAREHOLDERS EQUITY
Retained Earnings -$20.20M
YoY Change -3.76%
Common Stock $8.000K
YoY Change 14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.99M
YoY Change
Total Liabilities & Shareholders Equity $72.08M
YoY Change -5.81%

Cashflow Statement

Concept 2024 Q2 2024 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41376
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
DECISIONPOINT SYSTEMS, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1644635
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1615 South Congress Avenue Suite 103
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Delray Beach
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33445
CY2024Q1 dei City Area Code
CityAreaCode
(561)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
900-3723
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
DPSI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7681000 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5834000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4300000 usd
CY2024Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
324000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
267000 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19292000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23768000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1193000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2133000 usd
CY2024Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
4158000 usd
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
3826000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
598000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
630000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
31075000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
34657000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3208000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3392000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2889000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2973000 usd
CY2024Q1 us-gaap Deferred Costs
DeferredCosts
3744000 usd
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
3689000 usd
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1475000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1161000 usd
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7317000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7815000 usd
CY2024Q1 us-gaap Goodwill
Goodwill
22204000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
22081000 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000 usd
CY2024Q1 us-gaap Assets
Assets
72084000 usd
CY2023Q4 us-gaap Assets
Assets
75940000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
14575000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16857000 usd
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5607000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6566000 usd
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9222000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8066000 usd
CY2024Q1 dpsi Current Portion Of Earnout Consideration
CurrentPortionOfEarnoutConsideration
5550000 usd
CY2023Q4 dpsi Current Portion Of Earnout Consideration
CurrentPortionOfEarnoutConsideration
5370000 usd
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1003000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1003000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
888000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
874000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
36845000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38736000 usd
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5298000 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5307000 usd
CY2023Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1300000 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3388000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3639000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2862000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3093000 usd
CY2024Q1 dpsi Longterm Portion Of Earnout Consideration
LongtermPortionOfEarnoutConsideration
4692000 usd
CY2023Q4 dpsi Longterm Portion Of Earnout Consideration
LongtermPortionOfEarnoutConsideration
4316000 usd
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
53091000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
56397000 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7681000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7681000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7680000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7680000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
8000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
8000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
39184000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
38902000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20199000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19367000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18993000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19543000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72084000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75940000 usd
CY2024Q1 us-gaap Revenues
Revenues
25618000 usd
CY2023Q1 us-gaap Revenues
Revenues
27039000 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
19607000 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
20989000 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
6011000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
6050000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2813000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2368000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4096000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2494000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
6909000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4862000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-898000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1188000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
248000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
13000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1146000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1175000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-314000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
309000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-832000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
866000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7681 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7417 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7889 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7789 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
19543000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-832000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
279000 usd
CY2024Q1 dpsi Stock Issuedduringperiodvalue Cashless Exercise Of Warrants
StockIssuedduringperiodvalueCashlessExerciseOfWarrants
3000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18993000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16582000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
866000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
196000 usd
CY2023Q1 dpsi Stock Issuedduringperiodvalue Cashless Exercise Of Warrants
StockIssuedduringperiodvalueCashlessExerciseOfWarrants
6000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
17650000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-832000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
866000 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
743000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
564000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
279000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
196000 usd
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-314000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10000 usd
CY2024Q1 us-gaap Provision For Other Losses
ProvisionForOtherLosses
57000 usd
CY2023Q1 us-gaap Provision For Other Losses
ProvisionForOtherLosses
68000 usd
CY2024Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
6000 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-45000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4419000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9413000 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-946000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1551000 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
387000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
212000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-32000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
75000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2282000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3507000 usd
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-526000 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1871000 usd
CY2024Q1 dpsi Leased Assets Obtained In Exchange For New Operating Lease Liabilities
LeasedAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
33000 usd
CY2023Q1 dpsi Leased Assets Obtained In Exchange For New Operating Lease Liabilities
LeasedAssetsObtainedInExchangeForNewOperatingLeaseLiabilities
24000 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1147000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6394000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3243000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1496000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-161000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-176000 usd
CY2023Q1 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
5000000 usd
CY2024Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
251000 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000 usd
CY2024Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-1300000 usd
CY2023Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
7000000 usd
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3000 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1548000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12005000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1534000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10333000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4300000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7642000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5834000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17975000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
147000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
7000 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
6000 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1: Description of Business </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DecisionPoint Systems, Inc., which we sometimes refer to as the “Company”, “we” or “us”, is an enterprise mobility systems integrator that sells, installs, deploys and repairs mobile computing, POS equipment and wireless systems that are used both within a company’s facilities and in the field. These systems generally include mobile computers, mobile application software, and related data capture equipment including bar code scanners and radio frequency identification (“RFID”) readers. We also provide services, consulting, staging, kitting, deployment, maintenance, proprietary and third-party software and software customization as an integral part of our customized solutions for our customers. The suite of products utilizes the latest technologies with the intent to make complex mobile technologies easy to use, understand and keep running within all vertical markets such as merchandising, sales and delivery, field service, logistics and transportation and warehouse management.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2023, we acquired 100% of the issued and outstanding shares of Macro Integration Services, Inc. (“Macro”). Macro is a value-added reseller (“VAR”) that buys point of sale mobile computing, scanning, printing, and wireless products from various manufacturers and distributors. Macro also provides professional services for project management, implementation, deployment, installations, upgrades, training, and support.</p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the accompanying condensed consolidated financial statements and these notes. Actual results could differ from those estimates and may result in material effects on our operating results and financial position. Significant estimates made in preparing the accompanying condensed consolidated financial statements include (but are not limited to) those related to revenue recognition, goodwill and long-lived valuations and impairment assessments, earnout obligations, income tax valuations, and stock-based compensation expense.</p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Credit is extended to all customers based on financial condition, and collateral is generally not required. Concentrations of credit risk with respect to trade receivables are limited because of the large number of customers comprising our customer base and dispersion across many different industries and geographies. Accordingly, we continually monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon our historical experience and any specific customer collection issues that we have identified. Although credit losses have historically been within our expectations and the provisions established, we cannot guarantee that it will continue to experience the same credit loss rates that it has in the past.</p>
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
125000 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
131000 usd
CY2024Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.275 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.267 pure
CY2024Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
14500000 usd
CY2024Q1 dpsi Total Aggregate Transaction Price
totalAggregateTransactionPrice
9200000 usd
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
13400000 usd
CY2023 dpsi Total Aggregate Transaction Price
totalAggregateTransactionPrice
8100000 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
13373000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
10352000 usd
CY2024Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
5195000 usd
CY2023Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
14958000 usd
CY2024Q1 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
3207000 usd
CY2023Q1 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
2817000 usd
CY2024Q1 dpsi Revenue Recognized From Additions
RevenueRecognizedFromAdditions
841000 usd
CY2023Q1 dpsi Revenue Recognized From Additions
RevenueRecognizedFromAdditions
5747000 usd
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
14520000 usd
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
16746000 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
0.2 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
0.2 usd
CY2024Q1 us-gaap Revenues
Revenues
25618000 usd
CY2023 us-gaap Revenues
Revenues
27039000 usd
CY2024Q1 us-gaap Accrual For Environmental Loss Contingencies Increase Decrease For Acquisitions And Divestitures
AccrualForEnvironmentalLossContingenciesIncreaseDecreaseForAcquisitionsAndDivestitures
25700000 usd
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
26300000 usd
CY2023Q3 dpsi Asset Acquisition Additional Consideration Transferred
AssetAcquisitionAdditionalConsiderationTransferred
100000 usd
CY2024Q1 dpsi Net Working Capital Adjustments
NetWorkingCapitalAdjustments
100000 usd
CY2024Q1 dpsi Earnout Target
EarnoutTarget
3800000 usd
CY2024Q1 dpsi Asset Acquisition Consideration Transferred Purchase Price
AssetAcquisitionConsiderationTransferredPurchasePrice
10500000 usd
CY2024Q1 dpsi Asset Acquisition Consideration Transferred Working Capital Excess
AssetAcquisitionConsiderationTransferredWorkingCapitalExcess
5899000 usd
CY2024Q1 dpsi Bank Indebtedness
BankIndebtedness
1837000 usd
CY2024Q1 dpsi Seller Party Expenses
SellerPartyExpenses
845000 usd
CY2024Q1 dpsi Cash Due
cashDue
13717000 usd
CY2024Q1 dpsi Consideration Paid
ConsiderationPaid
11000000 usd
CY2024Q1 dpsi Payments To Seller
PaymentsToSeller
1600000 usd
CY2023Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
37980000 usd
CY2023Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
2223000 usd
CY2023Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.3
CY2023Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.29
CY2024Q1 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
15240000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-7923000 usd
CY2024Q1 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
7317000 usd
CY2023Q4 us-gaap Finite Lived Customer Relationships Gross
FiniteLivedCustomerRelationshipsGross
15240000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-7425000 usd
CY2023Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
7815000 usd
CY2024Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
500000 usd
CY2023Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
400000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-832000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
866000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7681 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7417 shares
CY2024Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
208000 usd
CY2023Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
372000 usd
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7889 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7789 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2023Q1 dpsi Borrowed Amount
BorrowedAmount
7000000 usd
CY2024Q1 us-gaap Line Of Credit
LineOfCredit
0 usd
CY2024Q1 dpsi Minimum Loan Outstanding Of Bear Interest
MinimumLoanOutstandingOfBearInterest
150000 usd
CY2024Q1 us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
10000000 usd
CY2024Q1 dpsi Loan Agreement Description
LoanAgreementDescription
Under the Loan Agreement , as amended by the Amendment, we are subject to a variety of customary affirmative and negative covenants, including that we (i) maintain a ratio of total debt to EBITDA of not greater than 3.0:1.0 measured at the end of each quarter, (ii) maintain a fixed charge coverage ratio of not less than 1.35:1.00 to be measured as of the end of each fiscal quarter, and (iii) submit a pro-forma statement in advance showing compliance and overall satisfactory metrics post-acquisition should the Company use any loan under the Loan Agreement for any acquisition with a purchase price in excess of $1,500,000.
CY2024Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000 usd
CY2024Q1 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
0 usd
CY2023Q1 us-gaap Unsecured Debt
UnsecuredDebt
5000000 usd
CY2023Q2 dpsi Principal And Interest Amount
PrincipalAndInterestAmount
250000 usd
CY2024Q1 us-gaap Federal Home Loan Bank Advances Weighted Average Interest Rate
FederalHomeLoanBankAdvancesWeightedAverageInterestRate
0.078 pure
CY2024Q1 dpsi Outstanding Debt Amount Under Promissory Note
OutstandingDebtAmountUnderPromissoryNote
100000 usd
CY2023Q4 dpsi Outstanding Debt Amount Under Promissory Note
OutstandingDebtAmountUnderPromissoryNote
100000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
4391000 usd
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
1003000 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3388000 usd
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
218209 shares
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
1 pure
CY2024Q1 dpsi Percentage Of Voting Power
PercentageOfVotingPower
0.10 pure
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
416813 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.89
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
69500 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.51
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.15
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
666 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.15
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
485147 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.12
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y1M20D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1925000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
408685 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.12
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y1M2D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6047000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q1 dpsi Grant Rate
GrantRate
0.33 pure
CY2024Q1 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
1700000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
200000 usd
CY2024Q1 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10: Contingencies</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Litigation</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we are subject to litigation incidental to the conduct of our business. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in our opinion, individually or in the aggregate, no such lawsuits are expected to have a material effect on our condensed consolidated financial position or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentrations</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One customer accounted for 12% of consolidated revenue during the three months ended March 31, 2024, and one customer accounted for 20% of consolidated revenue during the three months ended March 31, 2023. Trade accounts receivable from one customer represented 14% of net consolidated receivables at March 31, 2024 and one customer represented 49% of net consolidated receivables at March 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Two vendors each accounted for 21% of all consolidated purchases during the three months ended March 31, 2024. Three vendors accounted for 33%, 26%, and 22% of all consolidated purchases during the three months ended March 31, 2023. No other vendor accounted for more than 10% of purchases during the three months ended March 31, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 31, 2024, two vendors accounted for 24% and 21% of total accounts payable. As of March 31, 2023, three vendors accounted for 35%, 29% and 20% of total accounts payable. No other vendor accounted for more than 10% of accounts payable as of March 31, 2024 and 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A significant decrease or interruption in business from our significant customers or vendors could have a material adverse effect on our business, financial condition and results of operations. Financial instruments that potentially expose us to a concentration of credit risk principally consist of accounts receivable. We sell product to a large number of customers in many different geographic regions. To minimize credit risk, we perform ongoing credit evaluations of our customers’ financial condition.</p>
CY2024Q1 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
10.22
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001505611

Files In Submission

Name View Source Status
0001213900-24-043159-index-headers.html Edgar Link pending
0001213900-24-043159-index.html Edgar Link pending
0001213900-24-043159.txt Edgar Link pending
0001213900-24-043159-xbrl.zip Edgar Link pending
dpsi-20240331.xsd Edgar Link pending
ea0205782-10q_decision.htm Edgar Link pending
ea020578201ex31-1_decision.htm Edgar Link pending
ea020578201ex31-2_decision.htm Edgar Link pending
ea020578201ex32-1_decision.htm Edgar Link pending
ea020578201ex32-2_decision.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
dpsi-20240331_def.xml Edgar Link unprocessable
dpsi-20240331_lab.xml Edgar Link unprocessable
dpsi-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ea0205782-10q_decision_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dpsi-20240331_cal.xml Edgar Link unprocessable